Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Eficode Has Earned the DevOps with GitHub on Microsoft Azure Advanced Specialization

Helsinki, Finland, April 21, 2022 - Eficode  has earned the DevOps with GitHub on Microsoft Azure advanced specialization, a validation of a services partner’s deep knowledge, extensive experience and proven success in implementing secure software development practices applying DevOps principles and using Azure and GitHub solutions. Only partners that meet stringent criteria around customer success and staff skilling, as well as pass a third-party audit of their DevOps technical practices, are able to earn the DevOps with GitHub on Microsoft Azure advanced

Read original

CS MEDICA A/S: CS MEDICA has been approved by Hong Kong Custom and has received a trial order for the Hong Kong market

CS MEDICA (”CS MEDICA” or the ”Company”) announces today that the Company has been approved by the Hong Kong customs and is now able to sell its CANNASEN® CBD products in Hong Kong.  The Company has just received its first trial order from its sponsor/importer in Hong Kong.CS MEDICA has just received the final approval from Hong Kong customs, the Drug Registration Office, confirming that the CANNASEN® CBD product line can be sold to Hong Kong.  With reference to the less than 1PPB THC certificates showing zero traces of THC, the CANNASEN® CBD product line can be sold in Hong Kong without

Q-Free: SaaS contract in the USA - 28 MNOK

Q-Free has received an additional agreement for one of its key statewide ATMS contracts in the USA. The agreement adds scope to provide cloud infrastructure hosting and respective cloud support for Q-Free's OpenTMS solution for an initial period from April 2022 until June 2023 and has a total value of approximately 28 MNOK. The agreement could be prolonged for several years. - We are very pleased to see that Q-Free has continued to expand its ATMS cloud deployments and that the customer has decided to expand the scope of services Q-Free provides. The agreement gives us a nice and steady

BioStock: Immunicum participates in new cancer research consortium

In an effort to bring new cancer treatments faster to patients, the Dutch National Growth Fund will support a new cancer research consortium called Oncode-PACT with 325 MEUR. Cancer therapy biotech Immunicum has announced being part of the consortium, contributing with its expertise in dendritic cell biology to design novel cancer immunotherapies.Read the article at biostock.se: https://www.biostock.se/en/2022/04/immunicum-participates-in-new-cancer-research-consortium/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF)

· First clinical study with a digital therapy (DTx) in patients with IPF to address the psychological symptom burden in this disease · First patient enrolled in US pilot phase leading up to the US pivotal phase of the study with expected start in H2 2022 · DTx aims to form a part of a differentiated offering in rare lung disease Gothenburg, April 21, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company, today announces the first patient enrolled in the pilot phase of COMPANION[1], a clinical study of a digital cognitive behavioral therapy for

Presentation of Probi’s Q1 report 2022

Probi’s report for the first quarter 2022 will be published on Tuesday, 26 April at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Tom Rönnlund and CFO Henrik Lundkvist will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://tv.streamfabriken.com/probi-q1-2022 The presentation can also be followed via a telephone conference on the following telephone number: Sweden: +46 8 50 55 83 55UK: +44 33 33

Finnair removes the face mask requirement on flights where it is not an authority requirement

Many countries are removing Covid-19-related restrictions due to the increasing vaccination coverage and the mild form of the recent virus variants. In line with this, Finnair is now lifting the requirement to wear a face mask on board all flights.   As of 25 April, customers and crew are no longer required to wear a face mask onboard Finnair flights, unless it is specifically required by the authorities of the destination or origin country.   Those who wish to continue to wear a mask when traveling are naturally welcome to do so. “The aircraft is regarded as a low-risk environment

BioStock: CombiGene strives for a broader pipeline

In 2021, Swedish gene therapy company CombiGene signed an exclusive, global license agreement for candidate CG01 with Spark Therapeutics, which entitles CombiGene to up to 328.5 million USD excluding royalties. The parties are now putting the finishing touches on the preclinical work, after which Spark will be responsible for and pay for the first clinical studies in patients with drug-resistant focal epilepsy.Read the full article about CombiGene at biostock.se: https://www.biostock.se/en/2022/04/combigene-strives-for-a-broader-pipeline/ This is a press release from BioStock -

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 99 - 21 APRIL 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 56/2022. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

SelectImmune Pharma releases new film about immunotherapy

Today we are proud to present a new film entitled “Immunotherapy - a complement to antibiotics’’. The film tells the story about SelectImmune Pharma’s drug development program and the scientific discoveries that have defined new and exciting tools for treating infections. SelectImmune is developing several drug candidates with exciting potential. In the film you will meet the multinational and talented research team and hear their stories about their favourite molecules and technologies. You will also meet Dr. Björn Wullt, who has used innate immunotherapy to treat patients with bladder

New Nordic Schools releases Kwizie to help teachers instantly create engaging and inspiring quizzes with AI

Kwizie instantly creates and grades quizzes from any text-based resource, giving insights into each student’s level of understanding and saving teachers endless hours.Finnish education company  New Nordic Schools  launches  Kwizie  – an online tool that helps teachers engage with their students and save endless hours by instantly creating and grading quizzes with cutting-edge Artificial Intelligence (AI).  

Reading Rewards: Readly partners with Virgin Red

                                                                                                                                                                     Fancy earning loyalty points by reading your favourite newspapers and magazines? Well now you can! Virgin Red, Virgin’s rewards club, has partnered with Readly, the digital magazine and newspaper app, to offer members up to 750 Virgin Points and their first month free when they sign-up to Readly through Virgin Red.   Readly’s  subscription service offers unlimited digital access to more

Invitation to presentation of Coor’s Q1 2022 Report on April 29, 2022

Invitation to presentation of Coor’s Q1 2022 Report on April 29, 2022.Coor Service Management will be publishing its Q1 2022 Report on April 29, at 13:00 CEST. Accordingly, we’re inviting investors, analysts and media to a webcast (in English) on April, 29, at 14:00 CEST, where Coor’s President and CEO AnnaCarin Grandin together with CFO and IR Director Klas Elmberg will present and comment on the Interim Report.   To participate in the webcast, please register in advance via the following link: https://onlinexperiences.com/Launch/QReg/ShowUUID=C6B47941-F472-4DEC-BC23-D136DC7D7AE1

Nordea Bank Abp: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (BlackRock, Inc.)

Nordea Bank AbpStock exchange release – Major shareholder announcements21 April 2022 at 10.00 EET Nordea Bank Abp has on 20 April 2022 received a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which BlackRock, Inc.'s indirect shareholding of Nordea Bank Abp’s shares and voting rights has decreased below the threshold of 5 per cent on 19 April 2022. The total number of shares and voting rights in Nordea Bank Abp is 3,860,317,333. Total positions of BlackRock, Inc. and its funds according to the notification: % of %

The growth trend continues to permeate the industry

Cinodes Q4 report shows that the listed consulting companies in Sweden and Finland had an average growth of 25% in Q4, and 15% in 2021. The Swedish IT consulting companies top the list, Much due to the high number of acquisitions. The Swedish market has slightly higher growth figures compared to Finland. Swedish consulting companies report an average growth of 16.7% over the year whilst Finnish companies grew by 8.8 % on average, in 2021.Exsitec, Knowit, Prevas and Finnish Gofore were the companies with the highest growth figures in Q4.   - The growth in Q4 has broken records, and we

Crown Energy confirms receipt of payment of USD 8 million

INSIDE INFORMATION: Crown Energy AB ("Crown Energy" or the "Company") is happy to inform the market that the second instalment of USD 8 million has been credited to the Company’s account today, as per the signed agreement of 20/10/21.On 20 October 2021 Crown Energy has entered into an agreement under which the purchaser has the right to acquire (or pre-empt any sale of) Crown Energy’s up-stream oil and gas assets (except for operations in South Africa).   Crown Energy announces today that the second instalment of USD 8 million has been credited to Company’s account. This corresponds

CLS has entered agreement with Quadia Diagnostic Imaging Center in Piaseczno, Poland on commercial evaluation of TRANBERG® Thermal Therapy System in MR-guided ablation of localized prostate cancer

Clinical Laserthermia Systems AB (publ) today announced that the company has entered an agreement with Quadia Diagnostic Imaging Center in Piaseczno, Poland on a commercial evaluation of its second-generation TRANBERG® Thermal Therapy System with Thermoguide™ Workstation in MR-guided stereotactic focal laser ablation of localized prostate cancer.“We are very pleased that Quadia, a private imaging center with well-established reputation on the Polish market as the leading site in the MRI diagnostics of prostate cancer and other urological malignancies, have decided to evaluate our second-

BioStock Studio: Expres2ion’s CEO gives status update

Biotech ExpreS2ion Biotechnologies – that develops vaccines for covid-19, breast cancer, influenza and malaria – is currently conducting a rights issue of 73 million SEK. CEO Bent U. Frandsen visited BioStock’s studio to give a status update on the covid-19 project, which is being developed together with Bavarian Nordic, and to tell us more about the rights issue.Watch the interview at biostock.se: https://www.biostock.se/en/2022/04/biostock-studio-expres2ions-ceo-gives-status-update/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Invitation to presentation of Inwido´s Q1 interim report on April 28

Inwido will publish its first quarter results on April 28, 2022 at 07:45 am CET.A webcast for investors, analysts and media will be held at 10.00 (CET) that same day. The report will be presented by Henrik Hjalmarsson, President and CEO and Peter Welin, CFO. The presentation will be held in English and will also be live webcasted at:https://www.inwido.com/investors/financial-reports-and-presentations Here you will also find the presentation material for the meeting before it starts. It will also be possible to take part of the webcast afterwards at Inwido.com. Registration is not

Carbiotix hires Chief Medical Officer to support product expansion efforts

Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has hired Dr. Richard A. Rosenbloom (M.D. & Ph.D.) as its new Chief Medical Officer (CMO). Richard has been an advisor to Carbiotix since 2019 and starting in May will assist the Company with CMO duties, product development, regulatory affairs, pharmacovigilance, safety and medical affairs. Richard has decades of experience working in the United States as a CMO, Medical Director and Director of Medical Affairs for both pharmaceutical and clinical research companies. As the new CMO, Richard will support the Company’s

Today is the last day on which TO3 series CLS subscription warrants can be traded

Today, April 21, 2022, is the last day on which subscription warrants from the TO3 series (the “subscription warrants”) issued by Clinical Laserthermia Systems AB (publ) (“CLS” or the “Company”) in connection with the rights issue of units and the directed issue of units carried out by the Company in April 2021 can be traded. The subscription warrants are traded on Nasdaq First North Growth Market. One (1) subscription warrant provides the right to subscribe for one (1) new class B share in CLS at a price of SEK 3.50. In the case of full exercising of all the subscription warrants, CLS will

Beijer Ref Q1 2022

"We began the year strongly with organic sales increase of 16 per cent. All of our geographical segments had positive developments and we report total sales growth of 31 per cent compared with the same period last year. Our southern hemisphere markets had a good summer season and the acquisitions in Asia Pacific (APAC) show good growth", says Christopher Norbye, CEO Beijer Ref. FIRST QUARTER · Organic sales rose 15.8 per cent in the quarter compared to the previous year. Acquisition effects were 10.0 per cent and currency effects were 5.6 per cent. Net sales increased by 31.4 per

There are no items matching the current filter
There are no more items matching the current filter
Back to top